| 9/20/23 |
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV |
| 8/29/23 |
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences |
| 8/3/23 |
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results |
| 7/26/23 |
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023 |
| 7/20/23 |
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness |
| 6/29/23 |
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer |
| 6/24/23 |
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D |
| 6/7/23 |
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023 |
| 6/5/23 |
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference |
| 5/17/23 |
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders |
